



Creating a Path to Cancer Free Communities. Step By Step

THE UNIVERSITY OF TEXAS

**MD Anderson
Cancer Center**

Making Cancer History®

Updates in Cancer Immunotherapy and Toxicity Management 2-Day Seminar

March 23- 24, 2018

Double Tree Hotel by Hilton
8181 Airport Blvd.
Houston, TX 77061

Time: 8 a.m.-4 p.m. Daily

**Goal: To Improve Adverse Event Management &
Application of Immunotherapy in Cancer
Management**

www.acecancerinc.org

PLANNING COMMITTEE

- Chairman: Aung Naing, MD
Associate Professor
Investigational Cancer Therapeutics Department
The University of Texas MD Anderson Cancer Center
713-563-0803
anaing@mdanderson.org
- Co-Chair: Jianjun Gao, MD
Associate Professor
Department of Urology
The University of Texas M.D. Anderson Cancer Center
713-563-4195
jgao1@mdanderson.org
- Co-Chair: Eucharia Iwuanyanwu, DHSC, PA-C, FAAPA
President, Ace Cancer Care, Inc.
Physician Assistant, Investigational Cancer Therapeutics
The University of Texas MD Anderson Cancer Center
713-792-9882
eiwuany@mdanderson.org
- Diane Barber, PhD, APRN, ANP-BC, AOCNP
Advanced Practice Nurse
Investigational Cancer Therapeutics
The University of Texas MD Anderson Cancer Center
713-563-0176
dbarber@mdanderson.org
- Joan Lim, PharmD, BCSP
Clinical Pharmacy Specialist
Pharmacy Clinical Programs
The University of Texas MD Anderson Cancer Center
713-792-2564
jlim@mdanderson.org
- Kristi J. English, CHCP
Manager, CME/Conference Management
The University of Texas MD Anderson Cancer Center
kjenglish@mdanderson.org

Seminar Goal:

There has been a paradigm shift in the management of patients with advanced cancer from “one size fits all” to providing personalized therapy tailored to the molecular landscape of the tumor. However, in recent years, breakthrough discoveries of immune checkpoints and durable responses observed with immunotherapeutic agents has been more transformative and has led to regulatory approval of the several checkpoint inhibitors for specific indications.

Prompted by the success of these checkpoint inhibitors, increasing number of immunotherapeutic agents are being investigated across the tumor board, which presents unique challenges to the treating physician. As immunotherapy works by unleashing the suppressed immune system to attack tumor cells rather than attacking the tumor cells directly, immunotherapeutic agents differ significantly from chemotherapeutic agents and consequently pose monitoring and managing toxicity challenges for medical teams, community oncologists, emergency room physicians, etc.

Furthermore, with success being made with these drugs, more and more cancer patients are demanding these drugs as first line therapies for the management of their cancers.

This seminar seek to provide an avenue to bring updates on the application of immunotherapy in treatment of various cancers and the management of their accompanying toxicities to community providers who are interested in winning the fight against cancer

Educational Objectives

After attending the activity, participants should be able to

- Demonstrate an understating of developmental therapeutics, the pathophysiology and application of the immunotherapy drugs (*knowledge, competence, performance*)
- Become competent in use of biomarkers and monitoring of response to immunotherapy drugs (*knowledge, competence*)
- Identify and avoid contraindications to immunotherapy drugs (*knowledge, competence, performance, patient outcomes*)
- Assess the application of immunotherapy drugs in cancer management including in combination with cytotoxic drugs, targeted therapy and radiation therapy (*knowledge, competence*)
- Recognize and manage toxicities associated with the drugs early to avoid disastrous outcomes for patients (*knowledge, competence, performance, patient outcomes*)

Target Audience

- Physicians
- Fellows/Students
- Physician Assistants
- Pharmacists
- Advanced Practice Registered Nurses
- Research Coordinators/Researchers
- Registered Nurses

Educational Methods

- Lectures • Case Presentation Including Interactive Audience Participation
- Question and Answer Sessions • Panel Discussions

Accreditation and Credit Designation

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The University of Texas MD Anderson Cancer Center and the Ace Cancer Care, Inc. The University of Texas MD Anderson Cancer Center is accredited by the ACCME to provide continuing medical education for physicians.

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 14.25 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

FACULTY LIST

Anne K. Brinkman, APRN

Advanced Prac Registered Nurse
Endocrine Neoplasia & HD
MD Anderson Cancer Center

Ahmed Elsayem, MD

Professor
Emergency Medicine
MD Anderson Cancer Center

Nathan Fowler, MD

Associate Professor
Lymphoma/Myeloma
MD Anderson Cancer Center

Jianjun Gao, MD

Associate Professor
Urology
MD Anderson Cancer Center

Isabella C Glitza Oliva, MD, PhD

Assistant Professor
Melanoma Medical Oncology
MD Anderson Cancer Center

Joud Hajjar, MD

Assistant Professor
Immunology, Allergy & Rheumatology
Baylor College of Medicine and Texas Children's
Hospital

Eucharía Iwuanyanwu, DHSc, PA-C

Physician Assistant
Investigational Cancer Therapeutics
MD Anderson Cancer Center

Sang Taek Kim, MD, PhD

Instructor
General Internal Medicine
MD Anderson Cancer Center

Altan Mehmet, MD

Assistant Professor
Thoracic/Head & Neck Medical Oncology
MD Anderson Cancer Center

Ethan Miller, MD

Assistant Professor
GI Herpetology & Nutrition
MD Anderson Cancer Center

Aung Naing, MD

Professor
Investigational Cancer Therapeutics
MD Anderson Cancer Center

Shubham Pant, MBBS

Associate Professor
Investigational Cancer Therapeutics
MD Anderson Cancer Center

Anish Patel, MD

Assistant Professor
Dermatology
MD Anderson Cancer Center

Vicki Shannon, MD

Professor
Pulmonary Medicine
MD Anderson Cancer Center

George Simon, MD

Professor
Thoracic/Head & Neck Medical Oncology
MD Anderson Cancer Center

Neeto Somaiah, MD

Assistant Professor
Sarcoma Medical Oncology
MD Anderson Cancer Center

Sudhaka Tummala, MD

Professor
Neurology
MD Anderson Cancer Center

March 23, 2018

7:30-8:00 a.m.	Breakfast
8:00-8:10 a.m.	Introduction of Program and First Speaker
8:10-8:50 a.m.	Immune system review and cancer escape mechanism Joud Hajjar, MD
8:50-9:40 a.m.	Immunotherapy and management of Head & Neck cancers: Updates Altan Mehmet, MD
9:40-10:20 a.m.	Advances in immunotherapy: Sarcomas Neeto Somaiah, MD
10:20-11:00	Advances in immunotherapy and Melanoma Management Isabella C Glitza Oliva, MD, PhD
11:00-11:10 a.m.	Break
11:10-11:35 a.m.	Biomarkers and correlates of clinical response in cancer immunotherapy Aung Naing, MD
11:35-12:00 p.m.	Panel Discussion
12:00- 12:50 p.m.	Lunch
12:50-1:30: p.m.	Immune based therapies in gastrointestinal cancers (Colon & Pancreatic) Shubham Pant, MBBS
1:30-2:10 p.m.	Lymphoma and Immunotherapy: Better Outcomes Nathan Fowler, MD
2:10-2:55 p.m.	Advances in immunotherapy in Bladder and Renal Cancers Jianjun Gao, MD
2:55-3:35 p.m.	Endocrine Toxicities Anne K. Brinkman, APRN
3:35-4:00 p.m.	Panel Discussion

March 24, 2018

7:30-8:00 a.m.	Breakfast
8:00-8:10 a.m.	Introduction of Program and First Speaker
8:10-9:00 a.m.	Dermatological toxicity: What to expect & management Anish Patel, MD
9:00-9:50 a.m.	Recognizing and managing gastrointestinal toxicities (ileitis Colitis, hepatitis, pancreatitis) Ethan Miller, MD
9:50-10:00 a.m.	Break
9:50-10:50 a.m.	Immunotherapy and Lung Cancer management: Updates George Simon, MD
10:50-11:30 a.m.	Immunotherapy pulmonary toxicity and management Vicki Shannon, MD
11:30-12:00 p.m.	Panel Discussion
12:00-12:50 p.m.	Lunch
12:50-1:30 p.m.	Autoimmune diseases: Contraindications to immunotherapy Sang Taek Kim, MD, PhD
1:30-2:00 p.m.	Education for the patient on immunotherapy Eucharía Iwuanyanwu, DHSc, PA-C
2:00-2:45 p.m.	Neurotoxicity of Immunotherapy and Management Sudhaka Tummala, MD
2:45-3:30 p.m.	Immunotherapy adverse event: A visit with the emergency room physician Ahmed Elsayem, MD
3:30-4:00 p.m.	Panel Discussion